Deutsche Bank raised the firm’s price target on AstraZeneca (AZN) to 11,500 GBp from 11,000 GBp and keeps a Sell rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s TAPER Study Targets Simpler Severe Asthma Care With Tezepelumab
- AstraZeneca’s Ondexxya Real-World Bleeding Study Update: What Investors Should Watch
- Trump Trade: Argentina says U.S. to cut hundreds of tariffs
- TrumpRx website using technology from GoodRx, STAT says
- AstraZeneca Targets Rare Bone Disorder Data in Russia, Laying Groundwork for Future HPP Opportunities